Atomoxetine for treatment of children and adolescents with ADHD
Resen, K.; Pagsberg, A.K.; Jörgens, G.
Ugeskrift for Laeger 176(10a)
2014
ISSN/ISBN: 1603-6824 PMID: 25350704 Document Number: 671732
Atomoxetine reduces ADHD symptoms in children and adolescents significantly and is indicated for ADHD with co-morbid anxiety, depression and tics or with an increased risk of abuse. Number needed to treat is 3.4-5. Common adverse effects are stomach pain, decreased appetite and somnolence. Serious adverse effects include increased vascular tone, decreased growth rate and increased suicidal behaviour. In most cases adverse effects are mild to moderate and transient. Since atomoxetine was launched in 2006, 117 cases of toxic exposures have been reported in Denmark.